FDA bans products from China plant used by Big Pharma players

A Chinese drug-ingredient maker who has produced active ingredients for some of the big guns in pharma now faces an FDA ban in the U.S. The agency added Zhejiang Hisoar Pharmaceutical to its import alert list after finding violations at a plant in Taizhou, Bloomberg reports. The company has made APIs for drugmakers including Novartis ($NVS), Sanofi ($SNY) and Pfizer ($PFE). More from FiercePharmaManufacturing

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.